A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: sIPV+bOPVBiological: wIPV+bOPV
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06752174
- Locations
- 🇨🇳
Shandong Provincial Center for Diseases Control and Prevention, Jinan, Shandong, China
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Phase 3
Recruiting
- Conditions
- Pneumococcal VaccinesPneumococcal Infections
- Interventions
- Biological: pneumococcal disease prevention
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 500
- Registration Number
- NCT06608199
- Locations
- 🇮🇩
Faculty of Medicine, padjadjaran University, Bandung, Indonesia
🇮🇩Universitas Padjadjaran Bandung, Bandung, Indonesia
🇮🇩Faculty of Medicine Udayana University, Denpasar, Indonesia
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
Phase 4
Completed
- Conditions
- Pneumonia
- Interventions
- Biological: PCV13
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 621
- Registration Number
- NCT06210737
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Phase 1
- Conditions
- COVID-19
- Interventions
- Biological: medium dosage inactivated SARS-CoV-2 vaccineBiological: high dosage inactivated SARS-CoV-2 vaccineBiological: Placebo
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 180
- Registration Number
- NCT04758273
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Phase 2
- Conditions
- COVID-19
- Interventions
- Biological: high dosage inactivated SARS-CoV-2 vaccineBiological: medium dosage inactivated SARS-CoV-2 vaccineBiological: Placebo
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 1000
- Registration Number
- NCT04756323
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried
Phase 3
- Conditions
- Haemophilus Influenzae Type b Infections
- Interventions
- Biological: Minhai-HIBBiological: Act-HIB®
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 1560
- Registration Number
- NCT02560272
- Locations
- 🇨🇳
Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Phase 3
Completed
- Conditions
- Meningitis
- Interventions
- Biological: MPV-A Vaccine GroupBiological: MCV-AC Vaccine GroupBiological: MCV-ACYW135 Vaccine GroupBiological: MPV-ACYW135 Vaccine GroupBiological: Hib Vaccine Group
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 2195
- Registration Number
- NCT02003495
- Locations
- 🇨🇳
Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
Phase 3
Completed
- Conditions
- Meningitis
- Interventions
- Biological: Group TBiological: Group C
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Target Recruit Count
- 1260
- Registration Number
- NCT02003313
- Locations
- 🇨🇳
Chaoyang District Centre for Disease Prevention and Control, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath